Iodothyronine deiodinase Inhibitors
3 drugsAbout Iodothyronine deiodinase
Iodothyronine deiodinases are enzymes that regulate thyroid hormone activity by catalyzing the removal of iodine atoms. This process influences thyroid hormone availability and maintains hormone homeostasis throughout the body.
Currently, there is no genetic evidence directly linking iodothyronine deiodinases to specific diseases. However, modulating thyroid hormone activity through these enzymes holds potential for therapeutic interventions.
Iodothyronine deiodinases are targeted by three FDA-approved small molecule drugs: Selenious Acid, Multrys, and Tralement. These drugs are marketed by AM REGENT for indications outside of typical disease areas.
Top Iodothyronine deiodinase Drugs
AM REGENT is the only company with approved drugs targeting iodothyronine deiodinases.
The market is highly concentrated, posing a barrier to entry for new competitors.
Iodothyronine deiodinase Drug Modality Landscape
Modalities
Routes of Administration
Iodothyronine deiodinase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Iodothyronine deiodinase Clinical Trials 45 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Iodothyronine deiodinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 15 | 11 | 0 | 4 | 100% |
| Phase 3 | 11 | 9 | 0 | 2 | 100% |
| Phase 4 | 15 | 12 | 2 | 1 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Iodothyronine deiodinase Drug Approval Timeline (2020 - 2020)
The first drug was approved in 2019, and the most recent in 2020, spanning a 2-year period.
Recent approvals suggest renewed interest, but short span may indicate limited future opportunities.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Iodothyronine deiodinase. A trial counts if an approved drug acting on Iodothyronine deiodinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.